PASG

Passage Bio Inc. (PASG) | Rumor.io

Passage Bio

PASG

Attention (50-day avg)0%

Attention rank (50-day avg)#4,049

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.03

Market capitalization15M

Earnings per share-11.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-45.5M

Social

What share of all stock conversation is about PASG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jun 25

Passage Bio, Inc. ($PASG) is merging with Remix Therapeutics in an all-stock deal, with Remix shareholders set to own approximately 93% of the combined company.
The new company, trading under ticker $RMTX, will focus on RNA-targeted small-molecule therapy, marking a shift from Passage Bio's gene therapy story.
The merger includes an oversubscribed $100 million private placement, expected to fund the combined company's operations into 2028 and support key trial results for their lead asset.

Generated by AI

Sentiment

Of the messages about PASG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.39% +5.51
Bearish	—	—	—	4.61% -5.51

Mar 31

Passage Bio, Inc. (PASG) has a strong clinical pipeline, with key studies for FTD treatments showing advancing development and de-risking the program.
The company has successfully enrolled and dosed patients in key studies, signaling accelerating execution and operational leverage expansion.
Oppenheimer initiated coverage on PASG with an Outperform rating and a $30 price target, citing a buying opportunity ahead of key data in H1 2026.

Generated by AI

Topics

Of the messages about PASG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	87.86%
Analysts	—	—	—	4.35%
Controversies	—	—	—	1.05%
Earnings	—	—	—	0.15%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.6%

Announcements· Dec 20

Passage Bio, Inc. ($PASG) announced promising initial data from a Phase 1/2 clinical trial of PBFT02 in FTD-GRN, a treatment for frontotemporal dementia with granulin.
The trial showed initial safety and biomarker data from three cohort 1 patients, with PBFT02 demonstrating potential as a treatment for FTD-GRN.
Passage Bio's shares surged 29% on the news, with the company's stock price increasing to $0.81.

Technical Analysis· Mar 31

$PASG has broken out and increased by 19.58% to $7.39, targeting $9.35 as news on FTD trial progress fuels momentum.
$PASG has tested resistance at $6.64 and is now targeting $9.35, with a key resistance level at $7.39.
$PASG has confirmed a technical break, with a key resistance level at $6.64 broken, and is now targeting $9.79, driven by recent news on the upliFT-D study.

Generated by AI

Community

Of the messages about PASG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	53.28%
Newcomers	—	100%	100%	46.72%

Regulars· Mar 6

Passage Bio, Inc. reported a loss of $0.50, beating consensus estimates but missing Earnings Whisper estimates.
The company filed form 8-K and form 10-K with the SEC, reporting on earnings and recent business highlights.
Passage Bio's Q4 2022 earnings call transcript showed an EPS of -$2.50, with the company providing recent business highlights and financial results.

Newcomers· Mar 31

Passage Bio's stock price surged due to strong Q4 and FY 2025 financial results, which showed margin expansion and key clinical trial milestones.
The company's upliFT-D study advances with patient enrollments and dosing milestones, indicating strong clinical execution and pipeline momentum for its FTD programs.
Passage Bio's stock received an "Outperform" rating and a $30 price target from Oppenheimer, which contributed to the stock's increase.

Generated by AI

Also Discussed

Investors talking about PASG also mention

#	Name	Attention
1	JKL - iShares Morningstar Small-Cap Value ETF	——
2	AtomOneATONE	0%+0
3	Galecto Inc.GLTO	0%0
4	Akash NetworkAKT	0.01%-0.01
5	Atomera IncATOM	0%+0
6	OsmosisOSMO	0%+0
7	NGM - NGM Biopharmaceuticals, Inc.	——
8	TopBuild CorpBLD	0%new
9	BrightSpring Health Services, Inc.BTSG	0%new
10	AVRO - AVROBIO, Inc.	——

Passage Bio Inc.

Healthcare
Biotechnology

Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its current programs target rare, monogenic disorders of the central nervous system, with lead efforts centered on elevating progranulin levels and addressing underlying disease biology. The company’s pipeline includes clinical and early-stage candidates for conditions such as frontotemporal dementia, GM1 gangliosidosis, Krabbe disease, and other severe neurological disorders with limited treatment options. Passage Bio Inc. works in gene delivery and translational research to advance therapies designed for precise genetic correction or replacement within the brain and nervous system. Headquartered in Philadelphia, Pennsylvania, the company operates as a focused biotechnology developer within the genetic medicines field.

Website

Location

One Commerce Square

Philadelphia, PA, 19103

United States

Social

What share of all stock conversation is about PASG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jun 25

Passage Bio, Inc. ($PASG) is merging with Remix Therapeutics in an all-stock deal, with Remix shareholders set to own approximately 93% of the combined company.
The new company, trading under ticker $RMTX, will focus on RNA-targeted small-molecule therapy, marking a shift from Passage Bio's gene therapy story.
The merger includes an oversubscribed $100 million private placement, expected to fund the combined company's operations into 2028 and support key trial results for their lead asset.

Generated by AI

Sentiment

Of the messages about PASG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.39% +5.51
Bearish	—	—	—	4.61% -5.51

Mar 31

Passage Bio, Inc. (PASG) has a strong clinical pipeline, with key studies for FTD treatments showing advancing development and de-risking the program.
The company has successfully enrolled and dosed patients in key studies, signaling accelerating execution and operational leverage expansion.
Oppenheimer initiated coverage on PASG with an Outperform rating and a $30 price target, citing a buying opportunity ahead of key data in H1 2026.

Generated by AI

Topics

Of the messages about PASG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	87.86%
Analysts	—	—	—	4.35%
Controversies	—	—	—	1.05%
Earnings	—	—	—	0.15%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.6%

Announcements· Dec 20

Passage Bio, Inc. ($PASG) announced promising initial data from a Phase 1/2 clinical trial of PBFT02 in FTD-GRN, a treatment for frontotemporal dementia with granulin.
The trial showed initial safety and biomarker data from three cohort 1 patients, with PBFT02 demonstrating potential as a treatment for FTD-GRN.
Passage Bio's shares surged 29% on the news, with the company's stock price increasing to $0.81.

Technical Analysis· Mar 31

$PASG has broken out and increased by 19.58% to $7.39, targeting $9.35 as news on FTD trial progress fuels momentum.
$PASG has tested resistance at $6.64 and is now targeting $9.35, with a key resistance level at $7.39.
$PASG has confirmed a technical break, with a key resistance level at $6.64 broken, and is now targeting $9.79, driven by recent news on the upliFT-D study.

Generated by AI

Community

Of the messages about PASG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	53.28%
Newcomers	—	100%	100%	46.72%

Regulars· Mar 6

Passage Bio, Inc. reported a loss of $0.50, beating consensus estimates but missing Earnings Whisper estimates.
The company filed form 8-K and form 10-K with the SEC, reporting on earnings and recent business highlights.
Passage Bio's Q4 2022 earnings call transcript showed an EPS of -$2.50, with the company providing recent business highlights and financial results.

Newcomers· Mar 31

Passage Bio's stock price surged due to strong Q4 and FY 2025 financial results, which showed margin expansion and key clinical trial milestones.
The company's upliFT-D study advances with patient enrollments and dosing milestones, indicating strong clinical execution and pipeline momentum for its FTD programs.
Passage Bio's stock received an "Outperform" rating and a $30 price target from Oppenheimer, which contributed to the stock's increase.

Generated by AI

Passage Bio

Social

Jun 25

Sentiment

Mar 31

Topics

Announcements· Dec 20

Technical Analysis· Mar 31

Community

Regulars· Mar 6

Newcomers· Mar 31

Also Discussed

Passage Bio Inc.

Company Information

Location

Also Discussed

Social

Jun 25

Sentiment

Mar 31

Topics

Announcements· Dec 20

Technical Analysis· Mar 31

Community

Regulars· Mar 6

Newcomers· Mar 31